Original Article
Acyclovir and Transmission of HIV-1 from Persons Infected with HIV-1 and HSV-2
N Engl J Med 2010; 362:427-439February 4, 2010
- Abstract
Background
Most persons who are infected with human immunodeficiency virus type 1 (HIV-1) are also infected with herpes simplex virus type 2 (HSV-2), which is frequently reactivated and is associated with increased plasma and genital levels of HIV-1. Therapy to suppress HSV-2 reduces the frequency of reactivation of HSV-2 as well as HIV-1 levels, suggesting that suppression of HSV-2 may reduce the risk of transmission of HIV-1.
Methods
We conducted a randomized, placebo-controlled trial of suppressive therapy for HSV-2 (acyclovir at a dose of 400 mg orally twice daily) in couples in which only one of the partners was seropositive for HIV-1 (CD4 count, ≥250 cells per cubic millimeter) and that partner was also infected with HSV-2 and was not taking antiretroviral therapy at the time of enrollment. The primary end point was transmission of HIV-1 to the partner who was not initially infected with HIV-1; linkage of transmissions was assessed by means of genetic sequencing of viruses.
Results
A total of 3408 couples were enrolled at 14 sites in Africa. Of the partners who were infected with HIV-1, 68% were women, and the baseline median CD4 count was 462 cells per cubic millimeter. Of 132 HIV-1 seroconversions that occurred after randomization (an incidence of 2.7 per 100 person-years), 84 were linked within couples by viral sequencing: 41 in the acyclovir group and 43 in the placebo group (hazard ratio with acyclovir, 0.92, 95% confidence interval [CI], 0.60 to 1.41; P=0.69). Suppression with acyclovir reduced the mean plasma concentration of HIV-1 by 0.25 log10 copies per milliliter (95% CI, 0.22 to 0.29; P<0.001) and the occurrence of HSV-2–positive genital ulcers by 73% (risk ratio, 0.27; 95% CI, 0.20 to 0.36; P<0.001). A total of 92% of the partners infected with HIV-1 and 84% of the partners not infected with HIV-1 remained in the study for 24 months. The level of adherence to the dispensed study drug was 96%. No serious adverse events related to acyclovir were observed.
Conclusions
Daily acyclovir therapy did not reduce the risk of transmission of HIV-1, despite a reduction in plasma HIV-1 RNA of 0.25 log10 copies per milliliter and a 73% reduction in the occurrence of genital ulcers due to HSV-2. (ClinicalTrials.gov number, NCT00194519.)
Media in This Article
Figure 1
Enrollment and Follow-up of Participants.Figure 2
End Points with Respect to Transmission of HIV-1, According to the Study Group, in the Modified Intention-to-Treat and the Intention-to-Treat Populations.Article Activity
- Article
The seroprevalence of herpes simplex virus type 2 (HSV-2), the most common cause of genital ulcer disease worldwide, is 60 to 90% in populations with human immunodeficiency virus type 1 (HIV-1).1 Clinical manifestations of HSV-2 range from unrecognized or mild genital symptoms in most persons with HIV-1 infection to severe genital ulcer disease in persons with advanced HIV-1 disease.2,3 Genital shedding of the herpes simplex virus occurs on up to 30% of days in persons infected with HIV-1, often when they have no symptoms or observable lesions.4,5
Laboratory and epidemiologic studies suggest that HSV-2 may increase the infectiousness of HIV-1. HSV-encoded proteins bind integrated HIV-1 in coinfected cells and directly promote the transcription of HIV-1.6-9 In persons who are infected with both HIV-1 and HSV-2, symptomatic and asymptomatic reactivation of HSV-2 has been associated with increased HIV-1 levels in the blood and genital tract.10-13 In one study, the risk of transmission of HIV-1 to sexual partners was increased by a factor of 4 among persons with HIV-1 infection who had symptomatic genital ulcer disease, as compared with persons with HIV-1 who did not have genital ulcer disease; the majority of cases of genital ulcer disease were due to HSV-2 infection.14
Five randomized clinical trials showed that daily therapy for HSV-2 for 8 to 12 weeks reduced plasma HIV-1 levels by 0.25 to 0.50 log10 copies per milliliter.4,5,15-17 To evaluate directly whether HSV-2 suppressive therapy could prevent the transmission of HIV-1, we conducted a randomized, double-blind, placebo-controlled trial of acyclovir, administered twice daily, as compared with placebo, among African persons who were infected with both HIV-1 and HSV-2 and their heterosexual partners who were not infected with HIV-1.
Methods
Study Population
We enrolled heterosexual couples in which only one of the partners was seropositive for HIV-1 and that partner was also infected with HSV-2. Couples were recruited at seven sites in southern Africa (Gaborone, Botswana; Gugulethu, Orange Farm, and Soweto in South Africa; and Kitwe, Lusaka, and Ndola in Zambia) and seven sites in East Africa (Eldoret, Kisumu, Nairobi, and Thika in Kenya; Kigali, Rwanda; Moshi, Tanzania; and Kampala, Uganda) between November 2004 and April 2007, as previously described.18 The inclusion criteria for couples were three or more episodes of vaginal intercourse in the 3 previous months and the intention to remain together for at least 24 months. The inclusion criteria for partners infected with HIV-1 were an age of at least 18 years, seropositivity for HIV-1 and HSV-2, a CD4 count of 250 or more cells per cubic millimeter, no conditions associated with acquired immunodeficiency syndrome, and no current antiretroviral therapy. Exclusion criteria for persons infected with HIV-1 were previous adverse reactions to acyclovir, current receipt of therapy for HSV, persistent genital ulcers, current participation in another study, plans for extended travel, and current pregnancy. Inclusion criteria for partners who were not infected with HIV-1 were an age of at least 18 years and HIV-1 seronegativity; the partners who were not infected with HIV-1 could be eligible whether they were seropositive or seronegative for HSV-2.
The protocol was approved by the University of Washington Human Subjects Review Committee and the ethics review committees at all local and collaborating organizations. All study participants provided written informed consent in English or their local language. The Bill and Melinda Gates Foundation funded the study but did not assume responsibility for review of the protocol. The authors designed the study, wrote the protocol, had full access to the raw data, performed all analyses, wrote the manuscript, and had final responsibility for the decision to submit the manuscript for publication.
Enrollment
Partners with HIV-1 infection were randomly assigned in a 1:1 ratio to receive acyclovir, at a dose of 400 mg orally twice daily, or matching placebo; a block randomization scheme was used, with stratification according to site with the use of a pseudo–random-number generator. The study drug was manufactured by Ranbaxy Laboratories; matched active and placebo tablets were packaged in bottles that were distributed at monthly visits and were provided for the duration of the couples' participation in the study — up to 24 months. At all visits, participants, individually or as couples, received intensive counseling on risk reduction, were provided with condoms, and received treatment for sexually transmitted infections according to World Health Organization guidelines.
Follow-up
Visits for partners infected with HIV-1 were scheduled monthly to dispense the study drug or placebo, collect any unused drug from the preceding month, and provide counseling on adherence. Monthly adherence to the assigned treatment was assessed by means of pill counts and self-reporting of 100% adherence or less than 100% adherence. Interviews were conducted to obtain information regarding high-risk sexual practices in the previous month and symptoms of genital herpes in the previous 7 days. Participants with genital ulceration that was consistent with genital herpes were given open-label acyclovir at a dose of 400 mg three times daily for 5 days, in addition to the study drug; ulcers were swabbed and the specimens were sent for polymerase-chain-reaction (PCR) testing for HSV.
At quarterly visits, all participants underwent a genital examination, and urine samples were obtained from female participants for pregnancy testing. Women infected with HIV-1 who became pregnant were referred to antenatal clinics for services relating to the prevention of mother-to-child transmission, and the study medication was discontinued until a follow-up pregnancy test was negative. Participants with HIV-1 infection who met national guidelines for the initiation of antiretroviral therapy during the follow-up period were referred to local HIV-1 clinics. Partners who were not infected with HIV-1 were interviewed on a quarterly basis about high-risk sexual practices and symptoms of sexually transmitted infections and underwent antibody testing for HIV-1.
The laboratory procedures have been described previously18 and are summarized in the Supplementary Appendix, available with the full text of this article at NEJM.org. Study data were recorded on case-report forms and were submitted electronically to a database (DataFax, Clinical Datafax Systems) at DF/Net Research. All investigators except for one statistician and two data managers remained unaware of the randomization assignments until the completion of the study.
End Points
The primary end point was the acquisition of HIV-1 in partners who had not previously been infected; the diagnosis was made on the basis of a positive HIV-1–antibody test after a previously negative test. For participants who were found to have undergone seroconversion to HIV-1 at the first quarterly visit, plasma samples that had been obtained at the time of enrollment were tested for HIV-1 RNA; if the samples were positive, the couple was excluded from the analyses because HIV-1 infection occurred before randomization.
HIV-1 in the initially uninfected partner was classified as likely to have been acquired from the person's study partner (linked transmission) or likely to have been acquired from someone other than the person's study partner (unlinked transmission); the classification was based on the sequencing of plasma samples from the source partner and the newly infected partner for C2-V3-C3 regions of env (and, if needed, p17–p24 regions of gag), phylogenetic analysis, and posterior probability of linkage with the use of pairwise nucleotide distances between sequences (see the Supplementary Appendix). Members of an adjudication committee who were experts in HIV-1 sequencing and were unaware of the treatment assignments reviewed the sequencing data and provided a consensus classification of linkage (see the section on Determination of HIV-1 Transmission Linkage and Fig. 1 in the Supplementary Appendix).
Statistical Analysis
We estimated that with a sample of 3646 couples who were discordant for HIV-1 serologic status and a follow-up period of 12 months, and with the assumption that 85% of the transmissions of HIV-1 would be linked, 88 linked transmissions of HIV-1 would occur and the study would have 90% power to detect a 50% reduction in the incidence of HIV-1 infection in the acyclovir group as compared with the placebo group (from an estimated incidence of 4.0 per 100 person-years to 2.0 per 100 person-years), at a two-sided type I error rate of 5%. In December 2005, owing to a rate of enrollment that was slower than that projected, the protocol was modified to call for the enrollment of 3000 couples for up to 24 months of follow-up. A total of 96% of the partners infected with HIV-1 and 95% of the partners not infected with HIV-1 consented to participate in the extended follow-up. The study was reviewed by an independent data safety and monitoring board; the statistical analyses were monitored on the basis of the Lan–DeMets group sequential method with O'Brien–Fleming stopping boundaries.19,20
The primary analysis was a modified intention-to-treat analysis of linked transmissions of HIV-1; unlinked transmissions, seroconversions that occurred among men when their female partners who were infected with HIV-1 were pregnant and not taking the study drug, and seroconversions that occurred after the death of the HIV-1–infected partner were excluded. The secondary analysis was an intention-to-treat analysis of all HIV-1 transmissions that occurred after randomization, regardless of whether the transmission was linked or whether the HIV-infected person had been exposed to the study drug before seroconversion of his or her partner.
A proportional-hazards regression model, stratified according to site, was used to compare the time to the first positive HIV-1 test between the two study groups, and the Kaplan–Meier method was used to estimate the cumulative probability of infection with HIV-1. Subgroup analyses, defined a priori, were performed with the modified intention-to-treat data set according to the characteristics of the partner who was infected with HIV-1 (sex, presence or absence of genital ulcer disease before enrollment, baseline plasma HIV-1 RNA level, and average level of adherence to the study drug) and the partner who was not infected with HIV-1 (baseline HSV-2 serologic status and circumcision status in the case of men). Tests for differential treatment effects according to these characteristics were based on likelihood-ratio comparisons between models with appropriate interaction terms and those without appropriate interaction terms.
A linear mixed-effects model, with a random intercept, was used to evaluate the effect of the intervention on plasma concentrations of HIV-1 (log10 copies per milliliter) before the initiation of antiretroviral therapy, adjusted for the baseline concentrations of HIV-1.21 Generalized estimating equations with Poisson errors and robust variances were used to examine temporal trends in high-risk sexual practices. To evaluate the effect of treatment on genital ulcer disease in partners infected with HIV-1, the numbers of episodes of genital ulcer disease that were observed on examination over the course of the follow-up period were analyzed by log-linear regression, with (log-transformed) duration of follow-up as the offset term in the regression models, negative binomial errors, and robust variances. Reported P values are two-sided and were not adjusted for multiple comparisons.
Results
Study Participants
A total of 6543 couples who were discordant for HIV-1 serologic status were screened for the study; 3408 of these couples were enrolled. The partners who had HIV-1 infection were randomly assigned to receive acyclovir, at a dose of 400 mg twice daily, or placebo (Figure 1Figure 1
Enrollment and Follow-up of Participants.). After 24 couples in each group were excluded on the basis of confirmatory testing for HIV-1 and HSV-2, the final analysis included 3360 couples (1683 in the acyclovir group and 1677 in the placebo group).The two groups had similar baseline characteristics (Table 1Table 1
Baseline Characteristics of the Participants, According to Study Group.). In the case of 68% of the couples, the partner who was infected with HIV-1 was the female partner. A total of 76% of the couples were married, and 90% lived together; among the couples living together, the mean duration of the partnership was 5 years. Partners with HIV-1 infection reported a median of six sexual acts with their partner in the month before enrollment. In partners infected with HIV-1, the median baseline CD4 count was 462 cells per cubic millimeter, and median HIV-1 plasma RNA levels were 3.9 log10 copies per milliliter in women and 4.3 log10 copies per milliliter in men. At the time of enrollment, 23% of the partners with HIV-1 infection reported having had symptoms of genital ulcer disease in the previous 3 months, and genital ulcers were observed on examination in 3% of all HIV-1–infected partners. Among the partners who did not have HIV-1 infection at enrollment, 68% were seropositive for HSV-2.Follow-up, Pregnancy, and Adherence to the Study Treatment
Of the couples who were eligible for 24 months of follow-up, 92% of the partners infected with HIV-1 and 84% of the partners without HIV-1 infection remained in the study for 24 months. Participants who were not infected with HIV-1 accounted for 4868 person-years of follow-up for the assessment of the incidence of HIV-1 infection.
Acyclovir or matching placebo was dispensed at 88% of the monthly visits. The reasons for not dispensing the study medication included missed visits (in 48% of cases), pregnancy (36%, accounting for 4% of the person-years of follow-up among all participants with HIV-1 infection and 6% of the person-years of follow-up among female participants, with similar rates in the two groups), death of the HIV-1–infected partner while the partner who was not infected with HIV-1 remained in the study (10%), and other reasons (5%). An assessment of pill counts suggested that participants took 96% of the dispensed doses. The product of the percentage of drug taken and the percentage of drug dispensed (85%) provides an overall measure of study-drug coverage during the follow-up period. Overall, 71% of participants with HIV-1 infection had at least 90% coverage, 26% had less than 90% coverage, and 3% had missing data at some visits. Acyclovir was not associated with severe side effects; only one person discontinued acyclovir owing to side effects (headaches).
Effect of Acyclovir on Transmission of HIV-1
Seroconversion to HIV-1 occurred in 132 initially uninfected partners, representing an incidence of 2.7 per 100 person-years (95% confidence interval [CI], 2.3 to 3.2) (Figure 2Figure 2
End Points with Respect to Transmission of HIV-1, According to the Study Group, in the Modified Intention-to-Treat and the Intention-to-Treat Populations.). A total of 38 transmissions (29%) were determined to be not genetically linked, as assessed by viral sequencing, probably reflecting HIV-1 infection from a person other than the study partner; 3 transmissions (2%) could not be classified. Of 91 genetically linked HIV-1 transmissions (69%), 6 were excluded because they occurred while women with HIV-1 infection were pregnant and were not taking the study drug, and 1 was excluded because the incorrect drug was dispensed at month 12. Thus, 84 linked transmissions of HIV-1 were included in the modified intention-to-treat analysis. The incidence of HIV-1 infection, calculated on the basis of linked HIV-1 transmissions, was 1.8 per 100 person-years (95% CI, 1.5 to 2.3) overall, 2.5 per 100 person-years (95% CI, 1.8 to 3.4) for male-to-female transmission, and 1.5 per 100 person-years (95% CI, 1.1 to 2.0) for female-to-male transmission (hazard ratio for male-to-female transmission as compared with female-to-male transmission, 1.65; 95% CI, 1.06 to 2.56; P=0.02). The difference between the rate of male-to-female transmission and the rate of female-to-male transmission was attenuated after adjustment for plasma HIV-1 RNA levels (hazard ratio, 1.33; 95% CI, 0.77 to 2.29).Of the 84 linked transmissions included in the primary modified intention-to-treat analysis, 41 occurred in the acyclovir group and 43 in the placebo group (hazard ratio with acyclovir, 0.92; 95% CI, 0.60 to 1.41; P=0.69) (Figure 3Figure 3
Kaplan–Meier Curves for the Modified Intention-to-Treat Analysis.). In the secondary intention-to-treat analysis of all transmissions, 67 occurred in the acyclovir group and 64 in the placebo group (hazard ratio with acyclovir, 0.99; 95% CI, 0.71 to 1.40; P=0.97) (Fig. 2 in the Supplementary Appendix).In prespecified subgroup analyses performed with the modified intention-to-treat data set, there were no significant differences in the treatment effect according to sex, baseline plasma concentration of HIV-1, presence or absence of symptoms of genital ulcer disease in the partner with HIV-1 infection in the 3 months before enrollment, level of adherence to the assigned treatment (<90% or ≥90%), baseline HSV-2 serologic status of the partner who was not infected with HIV-1, or circumcision status of male partners who were not infected with HIV-1 (Figure 4Figure 4
HIV-1 Seroconversion Events, Overall and within Subgroups.). Partners without HIV-1 infection who were HSV-2–seropositive were at increased risk for acquiring HIV-1, as compared with those who were HSV-2–seronegative (hazard ratio, 2.02; 95% CI, 1.15 to 3.57), corroborating previous epidemiologic observations.22 Effect of Acyclovir in Reducing Plasma HIV-1 Concentrations
The mean plasma concentration of HIV-1 during the follow-up period was 0.25 log10 copies per milliliter lower in the acyclovir group than in the placebo group (95% CI, 0.22 to 0.29; P<0.001) (Figure 5Figure 5
Plasma HIV-1 RNA Levels in Participants Infected with HIV-1, According to Study Group.). The reductions were similar in men and women (0.30 and 0.23 log10 copies per milliliter, respectively; P=0.10 for the interaction between sex and treatment). An effect of acyclovir was seen across all strata of baseline plasma viral loads. The reduction in plasma HIV-1 concentrations was greater among participants who had baseline plasma HIV-1 concentrations of less than 100,000 copies per milliliter than among those who had baseline concentrations of 100,000 or more copies per milliliter (0.27 vs. 0.10 log10 copies per milliliter; P=0.001 for the difference in acyclovir effect between the two viral-load strata). There was a significant association between the mean rate of adherence to treatment in the previous quarter and the reduction in plasma HIV-1 levels with acyclovir: the reduction in the plasma HIV-1 level was 0.16 log10 copies per milliliter when the adherence rate was less than 75%, 0.19 log10 copies per milliliter when the adherence rate was 75 to 89%, and 0.27 log10 copies per milliliter when the adherence rate was 90% or more (P=0.002).Protective Effect of Acyclovir against Genital Ulcer Disease
A total of 217 episodes of genital ulcer disease were observed over the course of the follow-up period in the acyclovir group, as compared with 550 episodes in the placebo group (risk ratio, 0.39; 95% CI, 0.32 to 0.48; P<0.001). The protective effect of acyclovir against genital ulcer disease was greater when the analysis was restricted to the cases of genital ulcer disease that were positive for HSV DNA as assessed by PCR testing (92 in the acyclovir group vs. 336 in the placebo group; risk ratio, 0.27; 95% CI, 0.20 to 0.36, P<0.001). There was no significant difference in the protective effect of acyclovir against genital ulcer disease according to sex or status with respect to self-reported symptoms of genital ulcer disease during the 3 months before enrollment (P=0.55 and P=0.77, respectively). Among participants infected with HIV-1, episodic acyclovir therapy was provided at 1.8% of the visits in the acyclovir group and 4.7% of the visits in the placebo group.
Serious Adverse Events
A total of 381 serious adverse events, including 77 deaths, were reported; the number of events and the reported causes were similar in the two study groups (see the Supplementary Appendix). No serious adverse events were reported as having been possibly or probably related to acyclovir therapy.
Sexual Practices
High-risk sexual practices reported by participants decreased significantly during the follow-up period. A total of 29% of the partners infected with HIV-1 reported having had unprotected sex during the month before enrollment, as compared with an average of 7% during the follow-up visits (P<0.001); the reductions were similar in the two groups (P=0.31). The proportion of participants not infected with HIV-1 who reported having had sex with a partner other than their study partner increased from 5.4% at baseline to 15.5% at 24 months (P<0.001), with no significant difference between the groups (P=0.36). Among participants who underwent seroconversion to HIV-1, transmissions that were not genetically linked within the partnership were significantly more common among those who reported having had sex with persons other than their study partner in the 6 months before seroconversion than among those who did not (79% vs. 23%, P<0.001).
Discussion
A standard dose of the HSV-2 suppressive drug acyclovir (400 mg twice daily) given for up to 24 months to persons who were infected with both HIV-1 and HSV-2 and who had CD4 counts of 250 or more cells per cubic millimeter, did not reduce transmission of HIV-1 to sexual partners, despite significant reductions in plasma HIV-1 concentrations and in the incidence of genital ulcer disease caused by HSV-2. Thus, the lack of efficacy of HSV-2 suppressive therapy in preventing the transmission of HIV-1 among participants in this study does not appear to have been caused by poor activity of acyclovir against HSV-2 or by poor adherence to treatment, as assessed by monthly pill counts and by serum acyclovir testing in a subgroup of participants (Supplementary Appendix).
Epidemiologic and laboratory data accumulated over the course of more than 20 years suggest that genital HSV-2 infection increases the infectiousness of persons with HIV-1 infection. Genital ulcer disease increased female-to-male transmission of HIV-1 by a factor of nearly 5 among clients of female sex workers,23 and symptomatic genital ulcer disease in partners infected with HIV-1 increased the per-contact risk of HIV-1 transmission by a factor of 4 among monogamous HIV-1–serodiscordant couples.14 Elevated HIV-1 levels in plasma and genital secretions have been associated with symptomatic and asymptomatic reactivation of genital HSV-2 infection.10-13,24 Moreover, in five placebo-controlled, randomized trials, plasma HIV-1 RNA levels were reduced by 0.25 to 0.5 log10 copies per milliliter when persons who were infected with both HIV-1 and HSV-2 but were not receiving antiretroviral therapy received standard doses of HSV-2 suppressive agents (valacyclovir at a dose of 500 mg twice daily or acyclovir at a dose of 400 to 800 mg twice daily) for 1 to 3 months.4,5,15-17 Although the effects of acyclovir therapy on HIV-1 replication were thought to be indirectly mediated through HSV-2, two recent in vitro studies suggest that acyclovir may also have direct activity in reducing the replication of HIV-1.25,26
We selected acyclovir and the 400-mg twice-daily dose for our study on the basis of the similar efficacy of acyclovir at this dose to a dose of 500 mg of valacyclovir twice daily in reducing symptomatic genital ulcer disease and asymptomatic reactivation of genital HSV-227 and on the basis of the availability of acyclovir in a low-cost generic formulation. In addition, the reductions in plasma HIV-1 levels observed with this dose of acyclovir are similar to those seen with valacyclovir when it is used to suppress HSV-2 infection in persons infected with both HIV-1 and HSV-2.4,5,15-17 The reduction in plasma HIV-1 levels that we observed was similar to that seen in previous studies; therefore, the lack of efficacy in reducing the transmission of HIV-1 does not appear to have been due to lack of adherence to treatment or to the formulation of the study drug, nor is it likely that the efficacy would have been improved if standard doses of valacyclovir rather than acyclovir had been used.
The lack of efficacy of acyclovir in reducing the transmission of HIV-1 in our study suggests that a greater reduction in HIV-1 levels is needed to reduce the risk of transmission. This indication that a greater reduction in the plasma viral load may have to be achieved provides information that can be useful in the development of other biomedical strategies for the prevention of HIV-1, such as the treatment of coexisting infections (e.g., malaria or helminthic infection), and in the development of HIV-1 vaccines directed at reducing the HIV-1 viral load.28,29
Most transmissions of HIV-1 infection in Africa are thought to occur within stable, cohabiting HIV-1–serodiscordant couples.30 Our study shows the feasibility of conducting trials involving such couples18,31 to directly evaluate the efficacy of preventive strategies in decreasing the infectiousness of persons infected with HIV-1. The rate of HIV-1 transmission in our study population was 2.7 cases per 100 person-years overall, which is substantially lower than the rate in previous observational studies of HIV-1–serodiscordant couples.32,33 It is likely that the lower rate in our study was due largely to our having provided monthly counseling on risk reduction, free condoms, and other preventive services. Since approximately 30% of HIV-1 transmissions in this cohort of stable, cohabiting couples were attributable to outside partnerships, couples in which one of the partners is seropositive and the other is seronegative for HIV-1 should be counseled on potential misconceptions about the risk from sexual activity with other partners whose HIV-1 status is unknown.
In summary, our study of heterosexual HIV-1–serodiscordant couples showed that among the partners who were infected with both HIV-1 and HSV-2 and who had CD4 counts of 250 or more cells per cubic millimeter, treatment with standard doses of acyclovir for the suppression of HSV-2 infection did not decrease the incidence of transmission of HIV-1 to the uninfected partners, despite significant reductions in plasma HIV-1 levels and in the incidence of genital ulcer disease. New strategies to reduce the risk of transmission of HIV-1 are needed for HIV-1–serodiscordant couples.
Supported by a grant (26469) from the Bill and Melinda Gates Foundation. HIV-1 RNA testing and some computational analyses were also supported by a grant (AI-27757) from the University of Washington Center for AIDS Research Clinical Retrovirology and Computational Biology Cores. Roche HIV-1 RNA quality-assessment panels were obtained under the auspices of the University of Washington AIDS Clinical Trials Group Virology Support Laboratory (AI-38858). Herpes laboratory support was provided in part through a grant (NIAID P01 AI30731) from the Herpes Program Project. Dr. Whittington received support from Gen-Probe to undertake testing for this project. The community outreach recruitment strategy used by some sites was adapted from the Influence Network Agent model developed by Emory collaborators under a grant (NIMH R01 MH66767) from the National Institute of Mental Health, and the couples' voluntary HIV counseling and testing procedures were based on the CDC/NIMH/Liverpool School of Tropical Medicine procedure manual, which was developed in part through support from a grant (R01 MH66767) from the NIMH.
Dr. Celum reports receiving grant support from and serving on an advisory board for GlaxoSmithKline; Dr. Wald, receiving consulting fees from Immune Design, AiCuris, Astellas Pharma US, and MediGene and speaking fees from Merck Vaccines; Dr. Fife, receiving grant support from Astellas Pharma US and GlaxoSmithKline; Dr. Coombs, serving on an advisory board for Merck; Dr. Morrow, serving on an advisory board for Abbott Molecular, Biokit USA, and Roche Diagnostics; Dr. Whittington, receiving grant support from Cepheid; Dr. Ronald, receiving lecture fees from Merck; Dr. Essex, receiving royalties from Harvard University for use of the HIV gp 120/160 protein for diagnostics; and Dr. Corey, receiving consulting fees from AiCuris and GenPhar, receiving fees and equity shares (<1% ownership) for heading the scientific advisory board of Immune Design, and being named as a coinventor on several patents describing antigens and epitopes to which T-cell responses to HSV-2 are directed. The University of Washington Virology Division Laboratories have received grant funding from GlaxoSmithKline and Novartis to perform serologic assays for herpes simplex virus and polymerase-chain-reaction assays for studies funded by the companies; Dr. Corey directs these laboratories but receives no salary support from these grants. No other potential conflicts of interest relevant to this article were reported.
This article (10.1056/NEJMoa0904849) was published on January 20, 2010, at NEJM.org.
We thank the couples who participated in this study and the referral partners, community advisory groups, institutions, and communities that collaborated with the study sites; the members of the data safety and monitoring board (Drs. Richard Whitley [chair], Ann Arvin, Francis Kasolo, Alejandros Llanos, Jonathan Matenga, James Neaton, and David Serwadda) for their oversight and expertise; the members of the Endpoint Adjudication Committee (Drs. Jan Albert, Thomas Leitner, and Francine McCutchan) for their expertise and time in reviewing sequencing data and determining linkages; Toni Maddox for assistance with the preparation of an earlier version of the manuscript; and Drs. Deborah Donnell and Patrick Ndase for their contributions to the study and insightful comments on the analysis and on an earlier version of the manuscript.
Source Information
The authors' full names, degrees, and affiliations are listed in the Appendix.
Address reprint requests to Dr. Celum at the Department of Global Health, University of Washington, Harborview Medical Center, 325 Ninth Ave., Box 359927, Seattle, WA 98104.
Other members of the Partners in Prevention HSV/HIV Transmission Study Team are listed in the Supplementary Appendix, available with the full text of this article at NEJM.org.
Appendix
The authors' full names and degrees are as follows: Connie Celum, M.D., M.P.H., Anna Wald, M.D., M.P.H., Jairam R. Lingappa, M.D., Ph.D., Amalia S. Magaret, Ph.D., Richard S. Wang, M.S., Nelly Mugo, M.B., Ch.B., M.P.H., Andrew Mujugira, M.B., Ch.B., M.Sc., Jared M. Baeten, M.D., Ph.D., James I. Mullins, Ph.D., James P. Hughes, Ph.D., Elizabeth A. Bukusi, M.B., Ch.B., Ph.D., Craig R. Cohen, M.D., M.P.H., Elly Katabira, M.B., Ch.B., Allan Ronald, M.D., James Kiarie, M.B., Ch.B., M.P.H., Carey Farquhar, M.D., M.P.H., Grace John Stewart, M.D., Ph.D., Joseph Makhema, M.B., Ch.B., Myron Essex, D.V.M., Ph.D., Edwin Were, M.B., Ch.B., M.P.H., Kenneth H. Fife, M.D., Ph.D., Guy de Bruyn, M.B., B.Ch., M.P.H., Glenda E. Gray, M.B., B.Ch., James A. McIntyre, M.B., B.Ch., Rachel Manongi, M.D., Saidi Kapiga, M.D., Sc.D., David Coetzee, M.B., B.Ch., Susan Allen, M.D., M.P.H., Mubiana Inambao, M.D., M.P.H., Kayitesi Kayitenkore, M.D., Etienne Karita, M.D., M.Sc., William Kanweka, M.D., M.P.H., Sinead Delany, M.D., Ph.D., Helen Rees, M.B., B.S., Bellington Vwalika, M.D., M.Sc., Wendy Stevens, M.B., B.Ch., Mary S. Campbell, M.D., Katherine K. Thomas, M.S., Robert W. Coombs, M.D., Ph.D., Rhoda Morrow, Ph.D., William L.H. Whittington, A.B., M. Juliana McElrath, M.D., Ph.D., Linda Barnes, M.H.A., Renee Ridzon, M.D., and Lawrence Corey, M.D.
The authors' affiliations are as follows: the Departments of Global Health (C.C., J.R.L., R.S.W., N.M., A.M., J.M.B., E.A.B., G.J.S., M.J.M., L.B.), Epidemiology (C.C., A.W., C.F., G.J.S.), Medicine (C.C., A.W., J.R.L., J.M.B., J.I.M., C.F., G.J.S., M.S.C., K.K.T., R.W.C., W.L.H.W., M.J.M., L.C.), Laboratory Medicine (A.W., A.S.M., J.I.M., R.W.C., R.M., L.C.), Microbiology (J.I.M.), Pediatrics (J.R.L.), and Biostatistics (J.P.H.), University of Washington; Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center (A.W., A.S.M., M.J.M., L.C.); and the Bill and Melinda Gates Foundation (R.R.) — all in Seattle; the Department of Obstetrics and Gynecology, University of Nairobi and Kenyatta National Hospital (N.M., E.A.B., J.K.); and the Center for Microbiology Research, Kenya Medical Research Institute (E.A.B.) — both in Nairobi; and the Department of Reproductive Health, Moi University, Eldoret (E.W.) — all in Kenya; the Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, San Francisco (C.R.C.); the Infectious Disease Institute, Makerere University, Kampala, Uganda (E.K.); the Department of Medicine, University of Manitoba, Winnipeg, Canada (A.R.); Botswana–Harvard Partnership, Gaborone, Botswana (J.M.); the Department of Immunology and Infectious Diseases, Harvard School of Public Health, Harvard University, Boston (M.E.); the Department of Medicine, Indiana University, Indianapolis (K.H.F.); the Perinatal HIV Research Unit (G.B., G.E.G., J.A.M.), Reproductive Health and HIV Research Unit (S.D., H.R.); and Contract Laboratory Services (W.S.) — all at the University of the Witwatersrand, Johannesburg; and the Infectious Disease Epidemiology Unit, University of Cape Town, Cape Town (D.C.) — all in South Africa; Kilimanjaro Christian Medical Centre, Moshi, Tanzania (R.M., S.K.); the Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London (S.K.); the Rwanda–Zambia HIV Research Group and Emory University Schools of Medicine and Public Health, Atlanta (S.A., M.I., K.K., E.K., W.K., B.V.).
- References
References
1
Weiss H . Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 2004;11:Suppl 1:24A-35A
Medline2
Siegal FP ,Lopez C ,Hammer GS , et al. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med 1981;305:1439-1444
Full Text | Web of Science | Medline3
Strick LB ,Wald A ,Celum C . Management of herpes simplex virus type 2 infection in HIV type 1-infected persons. Clin Infect Dis 2006;43:347-356
CrossRef | Web of Science | Medline4
Zuckerman RA ,Lucchetti A ,Whittington WL , et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 2007;196:1500-1508
CrossRef | Web of Science | Medline5
Baeten JM ,Strick LB ,Lucchetti A , et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis 2008;198:1804-1808
CrossRef | Web of Science | Medline6
Kucera LS ,Leake E ,Iyer N ,Raben D ,Myrvik QN . Human immunodeficiency virus type 1 (HIV-1) and herpes simplex virus type 2 (HSV-2) can coinfect and simultaneously replicate in the same human CD4+ cell: effect of coinfection on infectious HSV-2 and HIV-1 replication. AIDS Res Hum Retroviruses 1990;6:641-647
CrossRef | Web of Science | Medline7
Diaz JJ ,Dodon MD ,Schaerer-Uthurralt N , et al. Post-transcriptional transactivation of human retroviral envelope glycoprotein expression by herpes simplex virus Us11 protein. Nature 1996;379:273-277
CrossRef | Web of Science | Medline8
Heng MC ,Heng SY ,Allen SG . Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus-1. Lancet 1994;343:255-258
CrossRef | Web of Science | Medline9
Mosca JD ,Bednarik DP ,Raj NB , et al. Herpes simplex virus type-1 can reactivate transcription of latent human immunodeficiency virus. Nature 1987;325:67-70
CrossRef | Web of Science | Medline10
Schacker T ,Ryncarz AJ ,Goddard J ,Diem K ,Shaughnessy M ,Corey L . Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998;280:61-66
CrossRef | Web of Science | Medline11
Schacker T ,Zeh J ,Hu H ,Shaughnessy M ,Corey L . Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002;186:1718-1725
CrossRef | Web of Science | Medline12
Mbopi-Keou F-X ,Gresenguet G ,Mayaud P , et al. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J Infect Dis 2000;182:1090-1096
CrossRef | Web of Science | Medline13
Baeten JM ,McClelland RS ,Corey L , et al. Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial. J Infect Dis 2004;189:1466-1471
CrossRef | Web of Science | Medline14
Gray RH ,Wawer MJ ,Brookmeyer R , et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001;357:1149-1153
CrossRef | Web of Science | Medline15
Nagot N ,Ouedraogo A ,Foulongne V , et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007;356:790-799
Full Text | Web of Science | Medline16
Dunne EF ,Whitehead S ,Sternberg M , et al. Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand. J Acquir Immune Defic Syndr 2008;49:77-83
CrossRef | Web of Science | Medline17
Delany S ,Mlaba N ,Clayton T , et al. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS 2009;23:461-469
CrossRef | Web of Science | Medline18
Lingappa JR ,Kahle E ,Mugo N , et al. Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the Partners Study. PLoS One 2009;4:e5272-e5272
CrossRef | Web of Science | Medline19
Lan KKG ,DeMets DL . Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-663
CrossRef | Web of Science20
O'Brien PC ,Fleming TR . A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556
CrossRef | Web of Science | Medline21
Laird NM ,Ware JH . Random-effects models for longitudinal data. Biometrics 1982;38:963-974
CrossRef | Web of Science | Medline22
Glynn JR ,Biraro S ,Weiss HA . Herpes simplex virus type 2: a key role in HIV incidence. AIDS 2009;23:1595-1598
CrossRef | Web of Science | Medline23
Cameron DW ,Simonsen JN ,D'Costa LJ , et al. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet 1989;2:403-407
CrossRef | Web of Science | Medline24
Mole L ,Ripich S ,Margolis D ,Holodniy M . The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997;176:766-770
CrossRef | Web of Science | Medline25
Lisco A ,Vanpouille C ,Tchesnokov EP , et al. Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. Cell Host Microbe 2008;4:260-270
CrossRef | Web of Science | Medline26
McMahon MA ,Siliciano JD ,Lai J , et al. The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J Biol Chem 2008;283:31289-31293
CrossRef | Web of Science | Medline27
Gupta R ,Wald A ,Krantz E , et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis 2004;190:1374-1381
CrossRef | Web of Science | Medline28
Walson JL ,Otieno PA ,Mbuchi M , et al. Albendazole treatment of HIV-1 and helminth co-infection: a randomized, double-blind, placebo-controlled trial. AIDS 2008;22:1601-1609
CrossRef | Web of Science | Medline29
Gilbert PB ,DeGruttola VG ,Hudgens MG ,Self SG ,Hammer SM ,Corey L . What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials. J Infect Dis 2003;188:179-193
CrossRef | Web of Science | Medline30
Dunkle KL ,Stephenson R ,Karita E , et al. New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data. Lancet 2008;371:2183-2191
CrossRef | Web of Science | Medline31
Lingappa JR ,Lambdin B ,Bukusi EA , et al. Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial. PLoS One 2008;3:e1411-e1411
CrossRef | Web of Science | Medline32
Quinn TC ,Wawer MJ ,Sewankambo N , et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000;342:921-929
Full Text | Web of Science | Medline33
Fideli US ,Allen SA ,Musonda R , et al. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses 2001;17:901-910
CrossRef | Web of Science | Medline
- Citing Articles (89)
Citing Articles
1
Nicholas J. Wagoner, Edward W. Hook. (2012) Herpes Diagnostic Tests and Their Use. Current Infectious Disease Reports
CrossRef2
A. L. Drake, A. C. Roxby, F. Ongecha-Owuor, J. Kiarie, G. John-Stewart, A. Wald, B. A. Richardson, J. Hitti, J. Overbaugh, S. Emery, C. Farquhar. (2012) Valacyclovir Suppressive Therapy Reduces Plasma and Breast Milk HIV-1 RNA Levels During Pregnancy and Postpartum: A Randomized Trial. Journal of Infectious Diseases 205:3, 366-375
CrossRef3
Leigh F. Johnson, Rob E. Dorrington, Debbie Bradshaw, David J. Coetzee. (2012) The role of sexually transmitted infections in the evolution of the South African HIV epidemic. Tropical Medicine & International Health 17:2, 161-168
CrossRef4
J. P. Hughes, J. M. Baeten, J. R. Lingappa, A. S. Magaret, A. Wald, G. de Bruyn, J. Kiarie, M. Inambao, W. Kilembe, C. Farquhar, C. Celum, . (2012) Determinants of Per-Coital-Act HIV-1 Infectivity Among African HIV-1-Serodiscordant Couples. Journal of Infectious Diseases 205:3, 358-365
CrossRef5
Oliver Laeyendecker, Ron Brookmeyer, Caroline Mullis, Deborah Donnell, Jairam Lingappa, Connie Celum, Jared M. Baeten, Mary S. Campbell, Max Essex, Guy de Bruyn, Carey Farquhar, Thomas C Quinn, Susan Eshleman. (2012) Specificity of four laboratory approaches for cross-sectional HIV incidence determination: Analysis of samples from adults with known non-recent HIV infection from five African countries. AIDS Research and Human Retroviruses120129065711008
CrossRef6
Arlene C. Sena, Peter Leone. (2012) Utility of Episodic Acyclovir Therapy for HSV-2 in Africa. Sexually Transmitted Diseases 39:1, 25-27
CrossRef7
Justin J. O’Hagan, Miguel A. Hernán, Rochelle P. Walensky, Marc Lipsitch. (2012) Apparent declining efficacy in randomized trials. AIDS 26:2, 123-126
CrossRef8
Patrick Ndase, Connie Celum, Katherine Thomas, Deborah Donnell, Kenneth H. Fife, Elizabeth Bukusi, Sinead Delany-Moretlwe, Jared M. Baeten. (2012) Outside Sexual Partnerships and Risk of HIV Acquisition for HIV Uninfected Partners in African HIV Serodiscordant Partnerships. JAIDS Journal of Acquired Immune Deficiency Syndromes 59:1, 65-71
CrossRef9
Philippe Van de Perre, Nicolas Nagot. (2012) Herpes simplex virus: a new era?. The Lancet
CrossRef10
Christine Johnston, Misty Saracino, Steve Kuntz, Amalia Magaret, Stacy Selke, Meei-li Huang, Joshua T Schiffer, David M Koelle, Lawrence Corey, Anna Wald. (2012) Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. The Lancet
CrossRef11
Douglas W. White, R. Suzanne Beard, Erik S. Barton. (2012) Immune modulation during latent herpesvirus infection. Immunological Reviews 245:1, 189-208
CrossRef12
Renee Heffron, Deborah Donnell, Helen Rees, Connie Celum, Nelly Mugo, Edwin Were, Guy de Bruyn, Edith Nakku-Joloba, Kenneth Ngure, James Kiarie, Robert W Coombs, Jared M Baeten. (2012) Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. The Lancet Infectious Diseases 12:1, 19-26
CrossRef13
Matthew Freeman, Michael Zychowicz, Gary Feldman, Shelley Gordon. (2012) The roles of self-efficacy and pretest counseling in type 2 herpes simplex virus screening in asymptomatic adults. Journal of the American Academy of Nurse Practitionersno-no
CrossRef14
Vladimir Novitsky, Max Essex. (2012) Using HIV viral load to guide treatment-for-prevention interventions. Current Opinion in HIV and AIDS1
CrossRef15
S. H. Eshleman, S. E. Hudelson, A. D. Redd, L. Wang, R. Debes, Y. Q. Chen, C. A. Martens, S. M. Ricklefs, E. J. Selig, S. F. Porcella, S. Munshaw, S. C. Ray, E. Piwowar-Manning, M. McCauley, M. C. Hosseinipour, J. Kumwenda, J. G. Hakim, S. Chariyalertsak, G. de Bruyn, B. Grinsztejn, N. Kumarasamy, J. Makhema, K. H. Mayer, J. Pilotto, B. R. Santos, T. C. Quinn, M. S. Cohen, J. P. Hughes. (2011) Analysis of Genetic Linkage of HIV From Couples Enrolled in the HIV Prevention Trials Network 052 Trial. Journal of Infectious Diseases 204:12, 1918-1926
CrossRef16
J. M. Marrazzo, W. Cates. (2011) Interventions to Prevent Sexually Transmitted Infections, Including HIV Infection. Clinical Infectious Diseases 53:suppl 3, S64-S78
CrossRef17
K. Mugwanya, J. M. Baeten, N. R. Mugo, E. Irungu, K. Ngure, C. Celum. (2011) High-dose Valacyclovir HSV-2 Suppression Results in Greater Reduction in Plasma HIV-1 Levels Compared With Standard Dose Acyclovir Among HIV-1/HSV-2 Coinfected Persons: A Randomized, Crossover Trial. Journal of Infectious Diseases 204:12, 1912-1917
CrossRef18
C. Tanton, L. J. Abu-Raddad, H. A. Weiss. (2011) Time to Refocus on HSV Interventions for HIV Prevention?. Journal of Infectious Diseases 204:12, 1822-1826
CrossRef19
Carolyn Gardella. (2011) Herpes Simplex Virus Genital Infections: Current Concepts. Current Infectious Disease Reports 13:6, 588-594
CrossRef20
Christine Johnston, David M. Koelle, Anna Wald. (2011) HSV-2: in pursuit of a vaccine. Journal of Clinical Investigation 121:12, 4600-4609
CrossRef21
Sascha R Ellington, Caroline C King, Athena P Kourtis. (2011) Host factors that influence mother-to-child transmission of HIV-1: genetics, coinfections, behavior and nutrition. Future Virology 6:12, 1451-1469
CrossRef22
Kenneth Ngure, Renee Heffron, Nelly R. Mugo, Connie Celum, Craig R. Cohen, Josephine Odoyo, Helen Rees, James N. Kiarie, Edwin Were, Jared M. Baeten. (2011) Contraceptive method and pregnancy incidence among African women in HIV-1 serodiscordant partnerships. AIDS1
CrossRef23
(2011) Prevention of HIV-1 Infection with Antiretroviral Therapy. New England Journal of Medicine 365:20, 1934-1935
Full Text24
James D Shelton. (2011) Role of concurrency in generalised HIV epidemics. The Lancet 378:9806, 1843
CrossRef25
J. T. Schiffer, A. Magaret, S. Selke, L. Corey, A. Wald. (2011) Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy. Journal of Antimicrobial Chemotherapy 66:11, 2593-2600
CrossRef26
Martina Morris, Helen Epstein. (2011) Role of concurrency in generalised HIV epidemics. The Lancet 378:9806, 1843-1844
CrossRef27
Nelly Mugo, Sufia S. Dadabhai, Rebecca Bunnell, John Williamson, Eddas Bennett, Isaack Baya, Nelly Akinyi, Ibrahim Mohamed, Reinhard Kaiser. (2011) Prevalence of Herpes Simplex Virus Type 2 Infection, Human Immunodeficiency Virus/Herpes Simplex Virus Type 2 Coinfection, and Associated Risk Factors in a National, Population-Based Survey in Kenya. Sexually Transmitted Diseases 38:11, 1059-1066
CrossRef28
Frank Hoentjen, David T. Rubin. (2011) Infectious Proctitis: When to Suspect It Is Not Inflammatory Bowel Disease. Digestive Diseases and Sciences
CrossRef29
Alexander Birkmann, Guy Hewlett, Helga Rübsamen-Schaeff, Holger Zimmermann. (2011) Helicase–primase inhibitors as the potential next generation of highly active drugs against herpes simplex viruses. Future Virology 6:10, 1199-1209
CrossRef30
Edwin Were, Kathryn Curran, Sinead Delany-Moretlwe, Edith Nakku-Joloba, Nelly R. Mugo, James Kiarie, Elizabeth A. Bukusi, Connie Celum, Jared M. Baeten. (2011) A prospective study of frequency and correlates of intimate partner violence among African heterosexual HIV serodiscordant couples. AIDS 25:16, 2009-2018
CrossRef31
Timothy D. Mastro, Myron S. Cohen, Helen Rees. (2011) Antiretrovirals for safer conception for HIV-negative women and their HIV-1-infected male partners. AIDS 25:16, 2049-2051
CrossRef32
Nelly R. Mugo, Renee Heffron, Deborah Donnell, Anna Wald, Edwin O. Were, Helen Rees, Connie Celum, James N. Kiarie, Craig R. Cohen, Kayitesi Kayintekore, Jared M. Baeten. (2011) Increased risk of HIV-1 transmission in pregnancy. AIDS 25:15, 1887-1895
CrossRef33
Michael Isiah Sandlin, Christine Johnston, David Bowe, Misty Saracino, Timothy Schacker, Mary Shaughnessy, Lawrence Corey, Anna Wald. (2011) Clinician and Patient Recognition of Anogenital Herpes Disease in HIV Positive Men Who Have Sex With Men. Sexually Transmitted Diseases 38:9, 833-836
CrossRef34
Pierre-Alain Rubbo, Edouard Tuaillon, Nicolas Nagot, Aziz Alami Chentoufi, Karine Bolloré, Jacques Reynes, Jean-Pierre Vendrell, Lbachir Benmohamed, Philippe Van De Perre. (2011) HIV-1 Infection Impairs HSV-Specific CD4+ and CD8+ T-Cell Response by Reducing Th1 Cytokines and CCR5 Ligand Secretion. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:1, 9-17
CrossRef35
Ivan Kasamba, Elizabeth Sully, Helen A Weiss, Kathy Baisley, Dermot Maher. (2011) Extraspousal Partnerships in a Community in Rural Uganda With High HIV Prevalence: A Cross-Sectional Population-Based Study Using Linked Spousal Data. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:1, 108-114
CrossRef36
Cohen, Myron S., Chen, Ying Q., McCauley, Marybeth, Gamble, Theresa, Hosseinipour, Mina C., Kumarasamy, Nagalingeswaran, Hakim, James G., Kumwenda, Johnstone, Grinsztejn, Beatriz, Pilotto, Jose H.S., Godbole, Sheela V., Mehendale, Sanjay, Chariyalertsak, Suwat, Santos, Breno R., Mayer, Kenneth H., Hoffman, Irving F., Eshleman, Susan H., Piwowar-Manning, Estelle, Wang, Lei, Makhema, Joseph, Mills, Lisa A., de Bruyn, Guy, Sanne, Ian, Eron, Joseph, Gallant, Joel, Havlir, Diane, Swindells, Susan, Ribaudo, Heather, Elharrar, Vanessa, Burns, David, Taha, Taha E., Nielsen-Saines, Karin, Celentano, David, Essex, Max, Fleming, Thomas R., . (2011) Prevention of HIV-1 Infection with Early Antiretroviral Therapy. New England Journal of Medicine 365:6, 493-505
Full Text37
Elizabeth Montgomery, Ariane van der Straten, Kristine Torjesen. (2011) “Male Involvement” in Women and Childrenʼs HIV Prevention: Challenges in Definition and Interpretation. JAIDS Journal of Acquired Immune Deficiency Syndromes 57:5, e114-e116
CrossRef38
Ruanne V. Barnabas, Emily L. Webb, Helen A. Weiss, Judith N. Wasserheit. (2011) The role of coinfections in HIV epidemic trajectory and positive prevention. AIDS 25:13, 1559-1573
CrossRef39
Seth C. Kalichman, Chauncey Cherry, Denise White, Miche’l Jones, Tamar Grebler, Moira O. Kalichman, Mervi Detorio, Angela M. Caliendo, Raymond F. Schinazi. (2011) Sexual HIV Transmission and Antiretroviral Therapy: A Prospective Cohort Study of Behavioral Risk Factors Among Men and Women Living with HIV/AIDS. Annals of Behavioral Medicine 42:1, 111-119
CrossRef40
Gita Ramjee. (2011) Antiretroviral-based microbicides and oral pre-exposure prophylaxis for HIV prevention. Future Virology 6:8, 997-1014
CrossRef41
Daniel D. Bohl, Kenneth A. Katz, Kyle Bernstein, Ernie Wong, Henry Fisher Raymond, Jeffrey D. Klausner, Willi McFarland. (2011) Prevalence and Correlates of Herpes Simplex Virus Type-2 Infection Among Men Who Have Sex With Men, San Francisco, 2008. Sexually Transmitted Diseases 38:7, 617-621
CrossRef42
Maarten F. Schim van der Loeff, Alan G. Nyitray, Anna R. Giuliano. (2011) HPV Vaccination to Prevent HIV Infection: Time for Randomized Controlled Trials. Sexually Transmitted Diseases 38:7, 640-643
CrossRef43
Ruanne V Barnabas, Judith N Wasserheit, Yunda Huang, Holly Janes, Rhoda Morrow, Jonathan Fuchs, Karen E Mark, Martin Casapia, Devan V Mehrotra, Susan P Buchbinder, Lawrence Corey. (2011) Impact of Herpes Simplex Virus Type 2 on HIV-1 Acquisition and Progression in an HIV Vaccine Trial (the Step Study). JAIDS Journal of Acquired Immune Deficiency Syndromes 57:3, 238-244
CrossRef44
Christina Ludema, Stephen R Cole, Charles Poole, Haitao Chu, Joseph J Eron. (2011) Meta-analysis of randomized trials on the association of prophylactic acyclovir and HIV-1 viral load in individuals coinfected with herpes simplex virus-2. AIDS 25:10, 1265-1269
CrossRef45
Mark W. Hull, Julio Montaner. (2011) Antiretroviral Therapy: A Key Component of a Comprehensive HIV Prevention Strategy. Current HIV/AIDS Reports 8:2, 85-93
CrossRef46
Allan Ronald, Moses Kamya, Elly Katabira, W. Michael Scheld, Nelson Sewankambo. (2011) The Infectious Diseases Institute at Makerere University, Kampala, Uganda. Infectious Disease Clinics of North America 25:2, 369-383
CrossRef47
T. E. Dudek, E. Torres-Lopez, C. Crumpacker, D. M. Knipe. (2011) Evidence for Differences in Immunologic and Pathogenesis Properties of Herpes Simplex Virus 2 Strains From the United States and South Africa. Journal of Infectious Diseases 203:10, 1434-1441
CrossRef48
Amina A. Chaudhry, Gail Berkenblit, Allen L. Gifford, Joseph Cofrancesco, James Sosman, Lynn E. Sullivan. (2011) Update in HIV Medicine for the Generalist. Journal of General Internal Medicine 26:5, 538-542
CrossRef49
Peter Vickerman, Angela Devine, Anna M. Foss, Sinead Delany-Moretlwe, Philippe Mayaud, Gesine Meyer-Rath. (2011) The Cost-Effectiveness of Herpes Simplex Virus-2 Suppressive Therapy With Daily Aciclovir for Delaying HIV Disease Progression Among HIV-1-Infected Women in South Africa. Sexually Transmitted Diseases 38:5, 401-409
CrossRef50
Myron S. Cohen, Joseph J. Eron. (2011) Aciclovir Treatment for Human Immunodeficiency Virus-1: Is the “Juice Worth the Squeeze?”. Sexually Transmitted Diseases 38:5, 410-412
CrossRef51
J. M. Baeten, E. Kahle, J. R. Lingappa, R. W. Coombs, S. Delany-Moretlwe, E. Nakku-Joloba, N. R. Mugo, A. Wald, L. Corey, D. Donnell, M. S. Campbell, J. I. Mullins, C. Celum. (2011) Genital HIV-1 RNA Predicts Risk of Heterosexual HIV-1 Transmission. Science Translational Medicine 3:77, 77ra29-77ra29
CrossRef52
P. Anton, B. C. Herold. (2011) HIV Transmission: Time for Translational Studies to Bridge the Gap. Science Translational Medicine 3:77, 77ps11-77ps11
CrossRef53
Sarah Rodgers, Kieron S Leslie. (2011) Skin infections in HIV-infected individuals in the era of HAART. Current Opinion in Infectious Diseases 24:2, 124-129
CrossRef54
Brian E Ng, Lisa M Butler, Tara Horvath, George W Rutherford, Lisa M Butler. 2011. Population-based biomedical sexually transmitted infection control interventions for reducing HIV infection. .
CrossRef55
Ume L Abbas. (2011) Uptake of biomedical interventions for prevention of sexually transmitted HIV. Current Opinion in HIV and AIDS 6:2, 114-118
CrossRef56
Brenna L. Anderson, Susan Cu-Uvin. (2011) Clinical Parameters Essential to Methodology and Interpretation of Mucosal Responses. American Journal of Reproductive Immunology 65:3, 352-360
CrossRef57
Rupert Kaul, Craig R. Cohen, Duncan Chege, Tae J. Yi, Wangari Tharao, Lyle R. McKinnon, Robert Remis, Omu Anzala, Joshua Kimani. (2011) Biological Factors that May Contribute to Regional and Racial Disparities in HIV Prevalence. American Journal of Reproductive Immunology 65:3, 317-324
CrossRef58
K. E. Johnson, A. D. Redd, T. C. Quinn, A. N. Collinson-Streng, T. Cornish, X. Kong, R. Sharma, A. A. R. Tobian, B. Tsai, M. E. Sherman, G. Kigozi, D. Serwadda, M. J. Wawer, R. H. Gray. (2011) Effects of HIV-1 and Herpes Simplex Virus Type 2 Infection on Lymphocyte and Dendritic Cell Density in Adult Foreskins from Rakai, Uganda. Journal of Infectious Diseases 203:5, 602-609
CrossRef59
Kenneth H. Mayer, Kartik K. Venkatesh. (2011) Interactions of HIV, Other Sexually Transmitted Diseases, and Genital Tract Inflammation Facilitating Local Pathogen Transmission and Acquisition. American Journal of Reproductive Immunology 65:3, 308-316
CrossRef60
Holly Hagan, David C. Perlman, Don C. Des Jarlais. (2011) Sexual Risk and HIV Infection Among Drug Users in New York City: A Pilot Study. Substance Use & Misuse 46:2-3, 201-207
CrossRef61
Andrew Mujugira, Amalia S Magaret, Jared M Baeten, Connie Celum, Jairam Lingappa. (2011) Risk Factors for HSV-2 Infection among Sexual Partners of HSV-2/HIV-1 Co-Infected Persons. BMC Research Notes 4:1, 64
CrossRef62
Timothy L Mah, James D Shelton. (2011) Concurrency revisited: increasing and compelling epidemiological evidence. Journal of the International AIDS Society 14:1, 33
CrossRef63
Helen Epstein, Martina Morris. (2011) Concurrent partnerships and HIV: an inconvenient truth. Journal of the International AIDS Society 14:1, 13
CrossRef64
Dipankar Biswas, Biswajyoti Borkakoty, Jagadish Mahanta, Kamini Walia, Lahari Saikia, Brogen S Akoijam, Lobsang Jampa, Alia Kharkongar, Eric Zomawia. (2011) Seroprevalence and risk factors of herpes simplex virus type-2 infection among pregnant women in Northeast India. BMC Infectious Diseases 11:1, 325
CrossRef65
Andrea Ries Thurman, Meredith R. Clark, Gustavo F. Doncel. (2011) Multipurpose Prevention Technologies: Biomedical Tools to Prevent HIV-1, HSV-2, and Unintended Pregnancies. Infectious Diseases in Obstetrics & Gynecology 2011, 1-10
CrossRef66
J. M. Baeten, J. Lingappa, I. Beck, L. M. Frenkel, G. Pepper, C. Celum, A. Wald, K. H. Fife, E. Were, N. Mugo, J. Sanchez, M. Essex, J. Makhema, J. Kiarie, C. Farquhar, L. Corey. (2011) Herpes Simplex Virus Type 2 Suppressive Therapy with Acyclovir or Valacyclovir Does Not Select for Specific HIV-1 Resistance in HIV-1/HSV-2 Dually Infected Persons. Journal of Infectious Diseases 203:1, 117-121
CrossRef67
Janna Patterson, Jane Hitti, Stacy Selke, Meei-Li Huang, D. Heather Watts, Zane Brown, Lawrence Corey, Anna Wald. (2011) Genital HSV Detection among HIV-1-Infected Pregnant Women in Labor. Infectious Diseases in Obstetrics & Gynecology 2011, 1-4
CrossRef68
Diego F Cuadros, Philip H Crowley, Ben Augustine, Sarah L Stewart, Gisela García-Ramos. (2011) Effect of variable transmission rate on the dynamics of HIV in sub-Saharan Africa. BMC Infectious Diseases 11:1, 216
CrossRef69
Sinead Delany-Moretlwe, Jonathan Stadler, Philippe Mayaud, Helen Rees. (2011) Investing in the future: lessons learnt from communicating the results of HSV/ HIV intervention trials in South Africa. Health Research Policy and Systems 9:Suppl 1, S8
CrossRef70
H Burris, J Parkhurst, Y Adu-Sarkodie, P Mayaud. (2011) Getting research into policy - Herpes simplex virus type-2 (HSV-2) treatment and HIV infection: international guidelines formulation and the case of Ghana. Health Research Policy and Systems 9:Suppl 1, S5
CrossRef71
Joseph G. Sinkovics. (2010) Antileukemia and antitumor effects of the graft-versus-host disease: A new immunovirological approach. Acta Microbiologica et Immunologica Hungarica 57:4, 253-347
CrossRef72
Barb Lohman-Payne, Jennifer Slyker, Sarah L. Rowland-Jones. (2010) Immune-based Approaches to the Prevention of Mother-to-child Transmission of HIV-1: Active and Passive Immunization. Clinics in Perinatology 37:4, 787-805
CrossRef73
Richard Hayes, Deborah Watson-Jones, Connie Celum, Janneke van de Wijgert, Judith Wasserheit. (2010) Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning?. AIDS 24:Suppl 4, S15-S26
CrossRef74
Jerome LeGoff, Clare Tanton, Constance Delaugerre, Helen A Weiss, John Changalucha, David A Ross, Kokugonza Mugeye, Laurent Belec, Richard J Hayes, Deborah Watson-Jones. (2010) No selection of nucleoside reverse transcriptase inhibitor resistance associated mutations by acyclovir suppressive therapy in herpes simplex virus-2/HIV-1 dually infected persons. AIDS 24:16, 2595-2596
CrossRef75
Kenneth K. Mugwanya, Jared M. Baeten, Edith Nakku-Joloba, Elly Katabira, Connie Celum, Daniel Tisch, Christopher Whalen. (2010) Knowledge and Attitudes About Male Circumcision for HIV-1 Prevention among Heterosexual HIV-1 Serodiscordant Partnerships in Kampala, Uganda. AIDS and Behavior 14:5, 1190-1197
CrossRef76
Audrey Pettifor. (2010) Michel Caraël and Judith R. Glynn (editors)
HIV, Resurgent Infections and Population Change in Africa. Studies in Family Planning 41:3, 238-240
CrossRef77
Karen E Mark, Anna Wald, Amalia S Magaret, Stacy Selke, Steven Kuntz, Meei-Li Huang, Lawrence Corey. (2010) Rapidly Cleared Episodes of Oral and Anogenital Herpes Simplex Virus Shedding in HIV-Infected Adults. JAIDS Journal of Acquired Immune Deficiency Syndromes 54:5, 482-488
CrossRef78
Anatoli Kamali. (2010) What is new in HIV/AIDS research in developing countries?. Tropical Medicine & International Health 15:8, 975-980
CrossRef79
Rebecca F Baggaley, Christophe Fraser. (2010) Modelling sexual transmission of HIV: testing the assumptions, validating the predictions. Current Opinion in HIV and AIDS 5:4, 269-276
CrossRef80
Renee Heffron, Edwin Were, Connie Celum, Nelly Mugo, Kenneth Ngure, James Kiarie, Jared M. Baeten. (2010) A Prospective Study of Contraceptive Use Among African Women in HIV-1 Serodiscordant Partnerships. Sexually Transmitted Diseases1
CrossRef81
Helen Ward, Minttu Rönn. (2010) Contribution of sexually transmitted infections to the sexual transmission of HIV. Current Opinion in HIV and AIDS 5:4, 305-310
CrossRef82
Myron S Cohen, Sarah Fidler. (2010) HIV prevention 2010: where are we now and where are we going?. Current Opinion in HIV and AIDS 5:4, 265-268
CrossRef83
Kayvon Modjarrad, Sten H Vermund. (2010) Effect of treating co-infections on HIV-1 viral load: a systematic review. The Lancet Infectious Diseases 10:7, 455-463
CrossRef84
David Lewis. (2010) Modern Management of Genital Ulcer Disease—Frappez Fort et Frappez Vite. Sexually Transmitted Diseases1
CrossRef85
(2010) Acyclovir and Transmission of HIV-1 from Persons Infected with HIV-1 and HSV-2. New England Journal of Medicine 362:18, 1740-1742
Full Text86
P. D. Griffiths. (2010) More on the treatment of herpesvirus cofactors. Reviews in Medical Virology 20:3, 133-135
CrossRef87
Anne Buvé, Lutgarde Lynen. (2010) Treating HIV infection with drugs for HSV-2 infection?. The Lancet 375:9717, 782-784
CrossRef88
Jairam R Lingappa, Jared M Baeten, Anna Wald, James P Hughes, Katherine K Thomas, Andrew Mujugira, Nelly Mugo, Elizabeth A Bukusi, Craig R Cohen, Elly Katabira, Allan Ronald, James Kiarie, Carey Farquhar, Grace John Stewart, Joseph Makhema, Myron Essex, Edwin Were, Kenneth H Fife, Guy de Bruyn, Glenda E Gray, James A McIntyre, Rachel Manongi, Saidi Kapiga, David Coetzee, Susan Allen, Mubiana Inambao, Kayitesi Kayitenkore, Etienne Karita, William Kanweka, Sinead Delany, Helen Rees, Bellington Vwalika, Amalia S Magaret, Richard S Wang, Lara Kidoguchi, Linda Barnes, Renee Ridzon, Lawrence Corey, Connie Celum. (2010) Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. The Lancet 375:9717, 824-833
CrossRef89
Nancy S Padian, Sandra I McCoy, Jennifer E Balkus, Judith N Wasserheit. (2010) Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS 24:5, 621-635
CrossRef
